Observations placeholder

Tracleer and Bosentan

Identifier

015757

Type of Spiritual Experience

Hallucination

Number of hallucinations: 64

Background

A description of the experience

Bosentan is a dual endothelin receptor antagonist used in the treatment of pulmonary artery hypertension (PAH). It is licensed in the United States, the European Union and other countries by Actelion Pharmaceuticals for the management of PAH under the trade name Tracleer.

Bosentan is a competitive antagonist of endothelin-1 at the endothelin-A (ET-A) and endothelin-B (ET-B) receptors. Under normal conditions, endothelin-1 binding of ET-A or ET-B receptors causes constriction of the pulmonary blood vessels. By blocking this interaction, bosentan decreases pulmonary vascular resistance. Bosentan has a slightly higher affinity for ET-A than ET-B.

On Dec, 23, 2016 41,375 people reported to have side effects when taking Tracleer.
Among them, 8,524 people (20.6%) have Death

Time on Tracleer when people have Death  :

  < 1 month 1 - 6 months 6 - 12 months 1 - 2 years 2 - 5 years 5 - 10 years 10+ years
Death 11.77% 19.34% 12.87% 17.41% 27.25% 11.10% 0.25%

 

On Jan, 04, 2017 41,375 people reported to have side effects when taking Tracleer.
Among them, 64 people (0.15%) have Hallucination

Time on Tracleer when people have Hallucination  :

  < 1 month 1 - 6 months 6 - 12 months 1 - 2 years 2 - 5 years 5 - 10 years 10+ years
Hallucination 52.38% 19.05% 14.29% 14.29% 0.00% 0.00% 0.00%

Gender of people who have Hallucination when taking Tracleer  :

  Female Male
Hallucination 69.57% 30.43%

Age of people who have Hallucination when taking Tracleer  :

  0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Hallucination 0.00% 0.00% 0.00% 0.00% 0.00% 27.78% 5.56% 66.67%

The source of the experience

eHealthme

Concepts, symbols and science items

Concepts

Symbols

Science Items

Activities and commonsteps

Commonsteps

References